CROSSJECT (STU:74C) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:74C CROSSJECT STU:74C
48 GF Score
Price €1.31
GF Value €1.22
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is CROSSJECT Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

STU:74C
48GF Score
CROSSJECT STU:74C
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CROSSJECT (STU:74C) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.31 is trading 7.4% above its estimated GF Value™ of €1.22. GuruFocus considers CROSSJECT to be Fairly Valued.

Key valuation signals for STU:74C:

  • Dividend-Payout-to-FFO:
  • GF Value™: €1.22 vs. price of €1.31 (7.4% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the STU:74C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CROSSJECT Business Description

Other Exchanges ALCJ:France
Address 60L avenue du 14 Juillet, Chenôve, FRA, 21300
CROSSJECT manufactures and markets needle-free drug self-injection system.
48GF Score

Get the complete analysis for STU:74C

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price
€1.22
GF Value